# Viral Reactivation and Immune Dysfunction in ME/CFS: Recent Findings (2020–2025)

## Introduction  
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multisystem disease often triggered by infection and characterized by chronic fatigue, post-exertional malaise, cognitive impairment, autonomic dysfunction, and immune abnormalities ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=Myalgic%20encephalomyelitis%2Fchronic%20fatigue%20syndrome%20,at%20biomarker%20identification%20were%20focused)). A growing body of research from 2020–2025 has focused on the role of latent viral reactivations and immune dysregulation in ME/CFS, spurred in part by parallels with post-acute COVID-19 syndrome (long COVID) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=viral%20infections%20have%20been%20proposed,need%20to%20develop%20innovative%20bioinformatics)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Myalgic%20encephalomyelitis%2Fchronic%20fatigue%20syndrome%20,is%20unknown%2C%20and%20the%20complex)). This report reviews recent findings on: (1) the frequency and load of Epstein–Barr Virus (EBV), Human Herpesvirus 6 (HHV-6), and other viruses in ME/CFS vs. healthy controls, especially in mucosal samples; (2) the presence and significance of autoantibodies against type I interferons (IFN-I) in ME/CFS (particularly severe cases); (3) proposed models linking viral reactivation, immune “buffer” collapse, and autonomic dysregulation; (4) evidence for nonlinear dynamics or “attractor-like” disease states involving immune-autonomic feedback loops; and (5) candidate biomarkers and subtype frameworks (e.g. combining viral load and autoantibody status) to stratify patients and guide therapy. Peer-reviewed studies and high-quality preprints are prioritized. 

## Frequency and Viral Load of EBV, HHV-6, and Other Viruses in ME/CFS  
**EBV Reactivation:** Multiple recent studies indicate that latent EBV is more frequently reactivated in ME/CFS patients than in healthy individuals. A 2025 study by Nilsson et al. examined viruses in *sputum* (airway mucus) – a compartment where latent viruses can shed – from 13 ME/CFS patients vs. 10 healthy donors (plus 4 older controls and 2 immunosuppressed controls) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=An%20exhausted%20antiviral%20immune%20response,to%20possibly%20explain%20impaired%20viral)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=immunity,compared%20to%20controls%2C%20have%20a)). EBV DNA was detected in 85% of ME/CFS patients (11/13) compared to 50% of healthy controls (5/10), and the EBV viral load in sputum was significantly higher in ME/CFS (p ≈ 0.0256) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)). By contrast, a B-cell–depleted immunosuppressed control had no EBV detected ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=asthmatic%20donor%20who%20inhaled%20glucocorticoids,capacity)), consistent with EBV’s latency in B cells. Another group (Shikova et al. 2020) using plasma samples found active EBV in significantly more ME/CFS patients (evidence of lytic EBV in 52% of patients) than controls (16% of controls), with no differences in CMV or HHV-6 ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=significant%20difference%20between%20the%20two,p)). Table 1 summarizes key findings on viral presence from recent studies. Notably, an investigation in Belarus reported latent EBV genomes in circulating blood leukocytes of 40% of ME/CFS patients versus 0% of healthy controls ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)), suggesting a higher rate of EBV persistence in patients’ immune cells. This mounting evidence supports a scenario of frequent EBV reactivation or incomplete suppression in ME/CFS.

**HHV-6 and Other Herpesviruses:** HHV-6 is another latent herpesvirus of interest. In the Nilsson et al. sputum study, HHV-6 DNA was *detected* in ~46% of ME/CFS patients (6/13) and ~50% of healthy controls (5/10), with *comparable viral levels* in both groups ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=The%20presence%20of%20HHV6%20was,Figure%201)). Thus, HHV-6 reactivation in the airway was common in *both* patients and controls in that small sample, and not significantly different. However, other evidence links HHV-6 activity to illness severity. A 2022 study of 134 ME/CFS patients found HHV-6 DNA in blood more often in severe cases (detected in 61% of severe vs 23% of mild cases) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=and%20muscarinic%20acetylcholine%20receptors%20,median%20concentration%20was%20found%20between)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)). Patients with a high HHV-6 viral load (>1,000 copies/10^6^ PBMCs) tended to have more severe disease ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=with%20severe%20ME%2FCFS%2C%20in%2018%2F73,The)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)), suggesting uncontrolled HHV-6 may worsen the condition. Similarly, a meta-analysis in 2021 confirmed an association between HHV-6 infection and ME/CFS onset ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Similarly%2C%20HHV,6)). Intriguingly, Shikova et al. found no difference in HHV-6 DNAemia between patients and controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)), echoing earlier inconsistent results in blood. One explanation is that HHV-6 (and EBV) may reactivate *locally* in tissues even if not widely disseminated in blood ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=integration%20of%20the%20viral%20genome,that%20is%20only%20detected%20in)) ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=cohort%20of%20ME%2FCFS%20patients%20and,role%20of%20herpesviruses%20in%20ME%2FCFS)). Indeed, a groundbreaking 2022 study by Kasimir et al. used post-mortem tissue biopsies to show **tissue-specific** herpesvirus reactivation in ME/CFS: they detected abundant HHV-6 microRNA (miR-U14, a lytic marker) in various brain regions and spinal cord of ME/CFS patients *but not in controls* ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=specific%20localization%20of%20active%20HHV,between%20herpesvirus%20infection%20and%20ME%2FCFS)) ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=understanding%20potential%20co,ME%2FCFS)). They also found EBV protein (deoxyuridine triphosphate nucleotidohydrolase, EBV dUTPase) in the hippocampus and brainstem of ME/CFS patients, while none of the control tissues had EBV markers ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=understanding%20potential%20co,ME%2FCFS)). These findings provide direct evidence that latent EBV and HHV-6 can awaken in the central nervous system of ME/CFS patients, even when blood tests are negative. In sum, HHV-6 appears to establish a persistent, often subclinical presence in many people, but ME/CFS may involve more frequent or extensive reactivation in tissues or saliva ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Similarly%2C%20HHV,6%2C%20in%20the)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Localized%20reactivation%20of%20HHV,mortem%20biopsy%20samples%20%5B24)), potentially correlating with symptom severity ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)).

**Other Viruses (Adenovirus, etc.):** Researchers have also probed non-herpes viruses in ME/CFS. Human Adenovirus (HAdV), a common respiratory virus, was generally *absent* in healthy individuals but was detected in rare ME/CFS cases with severe immune dysfunction. In the sputum study, HAdV DNA was found in 1 out of 13 patients – notably, a young patient (22 years old) with very severe, long-term ME/CFS (wheelchair-bound) – and in none of the healthy controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=HAdV%20was%20detected%20in%20a,the%20time%20of%20sputum%20collection)). That same patient had concurrent EBV reactivation and slightly elevated anti-IFN autoantibodies (discussed below), suggesting a profoundly impaired antiviral state ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=level%2Fmore%20frequent%20release%20of%20the,up)). HAdV was also present in one immunosuppressed control using corticosteroids ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=HAdV%20was%20detected%20in%20a,the%20time%20of%20sputum%20collection)). These data imply that active adenovirus infection is *infrequent* in ME/CFS, but may emerge in the most severe or immunocompromised cases ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,and%20Herpesvirus%20Reactivation%20in%20Airways)). Consistent with this, population data show HAdV is uncommon in routine respiratory infections (~2% of cases) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=can%20have%20a%20role%20in,was%20detected%20%5B%20143)); sputum may be more sensitive than nasal swabs for detecting it ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=www,was%20detected%20%5B%20143)). Other persistent viruses have been linked to ME/CFS in subsets of patients, including enteroviruses and parvovirus B19. For example, investigations of stomach tissue reported a higher prevalence of enterovirus RNA and parvovirus DNA in ME/CFS patients than in controls ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Other%20viral%20agents%20have%20also,A%20recent%20review%20presented%20considerable)), and historical outbreak studies have implicated enteroviruses in past epidemics of ME/CFS ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=enterovirus%20RNA%20and%20parvovirus%20B19,48)). Additionally, the Ross River virus (an alphavirus) caused an outbreak of post-viral fatigue in Australia, highlighting that *acute* viral triggers can vary ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Other%20viral%20agents%20have%20also,by%20one%20or%20more%20enterovirus)). Table 1 (below) compares key viral findings across recent studies.

**Table 1. Recent findings on latent virus reactivation in ME/CFS vs healthy controls**  

| **Study (Year)**                         | **Sample**                | **EBV Detection** (ME/CFS vs Control)                 | **HHV-6 Detection** (ME/CFS vs Control)            | **Other Viruses**                           |
|------------------------------------------|---------------------------|-------------------------------------------------------|---------------------------------------------------|---------------------------------------------|
| **Nilsson et al., 2025** ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=The%20presence%20of%20HHV6%20was,Figure%201)) (Sweden) – Viruses in sputum | Sputum (oral/pharyngeal mucus) | EBV DNA in 85% of patients vs 50% of healthy donors (significantly higher copies/mL in ME/CFS, *p* = 0.0256) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)). All 4 elderly controls also EBV+ ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=number%20of%20EBV%20copies%2FmL%2C%20was,EBV%2C%20in%20its)). | HHV-6 DNA in ~46% of patients (6/13) vs 50% of healthy controls (5/10); no significant load difference ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=The%20presence%20of%20HHV6%20was,Figure%201)). | HAdV detected in 1 severe ME/CFS patient vs 0 controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=HAdV%20was%20detected%20in%20a,the%20time%20of%20sputum%20collection)). HCMV and SARS-CoV-2: 0 patients, only in immunosuppressed controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=positive%20%28Figure%201%20%29,126)). |
| **Shikova et al., 2020** ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)) (Bulgaria) – Viral PCR | Plasma (cell-free DNA)       | Active EBV (lytic phase) detected in 30/58 patients (52%) vs 8/50 controls (16%) (*p* = 0.0027) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=significant%20difference%20between%20the%20two,p)). | HHV-6 DNA: no significant difference (patients ~38%, controls ~30%) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=significant%20difference%20between%20the%20two,p)). | HCMV DNA: no difference (low in both) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,0256%29%20in%20ME%2FCFS%20patients)). |
| **Orlova et al., 2021** ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)) (Belarus) – Latent infections | PBMC (peripheral blood cells) | EBV persistent infection in 40% of patients vs 0% of controls ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)) (in sorted leukocyte subsets). | HHV-6 persistent infection in 46.7% of patients vs 10% of controls ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)). | HHV-7 in 73.3% of patients vs 25% of controls ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)) (significant excess in ME/CFS). |
| **Kasimir et al., 2022** ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=understanding%20potential%20co,ME%2FCFS)) (Germany) – Autopsy tissue study | Brain and spinal cord tissues (post-mortem) | **EBV** dUTPase protein detected in brain regions of 2 of 3 ME/CFS patients (midbrain, hippocampus) vs 0 of 4 controls ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=understanding%20potential%20co,ME%2FCFS)), indicating focal EBV reactivation in CNS. | **HHV-6** miRNA (miR-U14) highly expressed in multiple CNS regions of ME/CFS patients vs 0 controls ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=specific%20localization%20of%20active%20HHV,between%20herpesvirus%20infection%20and%20ME%2FCFS)) ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=Co,patients)), consistent with active HHV-6 in neural tissue. | — (Tissue study focused on EBV & HHV-6; other viruses not reported) | 

*Key:* EBV = Epstein–Barr Virus; HHV-6 = Human Herpesvirus-6; HAdV = Human Adenovirus; HCMV = Human Cytomegalovirus; PBMC = peripheral blood mononuclear cells; dUTPase = EBV deoxyuridine triphosphate nucleotidohydrolase (early lytic protein).

In summary, these findings reinforce a long-suspected theme: many ME/CFS patients harbor *higher levels or frequencies* of certain latent viruses (especially EBV, and to some extent HHV-6/7) compared to healthy people ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)). The effect is most pronounced when looking in tissues or fluids where viruses reside (saliva/sputum, lymphocytes, CNS tissue) rather than only in blood plasma. EBV stands out as a candidate: over 90% of adults carry EBV, but ME/CFS patients show signs of poor control over EBV latency, with frequent reactivation (shedding) in mucosa ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)) and possibly an “overload” of EBV antigens that could stimulate the immune system ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=Several%20studies%20have%20investigated%20the,p)). HHV-6 is also ubiquitous (>85% seroprevalence ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Similarly%2C%20HHV,6))), and while its active reactivation is harder to catch in blood, innovative methods (miRNA probes, etc.) now implicate HHV-6 activity in ME/CFS central nervous system pathology ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=specific%20localization%20of%20active%20HHV,between%20herpesvirus%20infection%20and%20ME%2FCFS)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Localized%20reactivation%20of%20HHV,mortem%20biopsy%20samples%20%5B24)). Importantly, not all ME/CFS patients have detectable viral reactivation – for example, some have no evidence of ongoing infection (“hit-and-run” immune effects have been proposed ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=lead%20to%20reactivation%20of%20latent,dysregulation%20in%20ME%2FCFS%20point%20to)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=cases%2C%20there%20is%20no%20conclusive,role%20in%20several%20autoimmune%20diseases))). Nonetheless, the subset with high viral loads may correspond to a distinct phenotype or severity level. Reactivated viruses (through persistent low-level infection) could drive chronic immune activation, as discussed next.

## Autoantibodies to Type I Interferons in ME/CFS  
Autoantibodies (auto-Abs) that neutralize type I interferons – the critical antiviral cytokines like IFN-α and IFN-β – have gained attention as a cause of severe viral illness. Such antibodies can disable a person’s antiviral defenses. They rose to prominence in COVID-19, where ~10% of life-threatening COVID-19 pneumonia cases were found to have anti-IFN-I autoantibodies ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=are%20reactivated%20latent%20viruses%2C%20including,SLE%29%20and%20Sj%C3%B6gren%E2%80%99s)). These auto-Abs have also been seen in a subset of patients with severe West Nile virus encephalitis, severe varicella or HCMV infections, disseminated adenovirus, and even in some healthy elderly individuals (around 4% of people over 70) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=AutoAbs%20to%20IFN,disseminated%20viral%20infections%20caused%20by)). Given that ME/CFS often follows an acute viral infection and shows an “exhausted” antiviral immune profile ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=%3A)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=healthy%20controls%20,ME%2FCFS%20case%20showing%20an%20increased)), researchers asked: do ME/CFS patients – especially the sickest – harbor interferon-blocking antibodies that could impair viral clearance?

A study by Nilsson *et al.* (2025) investigated this by measuring IgG autoantibodies against IFN-I in the **sputum** of ME/CFS patients and controls (sputum was used to sample the mucosal immune environment where viruses were detected) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=healthy%20controls%20,ME%2FCFS%20case%20showing%20an%20increased)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=immunity,compared%20to%20controls%2C%20have%20a)). The results showed that, on a group level, ME/CFS patients did **not** have significantly elevated anti-IFN-I autoantibodies compared to healthy controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,I%20in%20ME%2FCFS%20Patients)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=autoAbs%20to%20IFN,one%20control%20participant%2C%20treated%20with)). Both patients and controls generally showed low baseline levels of these antibodies in sputum. This suggests that *most* ME/CFS cases are not driven by the kind of IFN-neutralizing autoimmunity seen in severe COVID-19. However, there were **notable exceptions**: one ME/CFS patient – specifically the individual with severe, longstanding disease (patient “Id12,” who had high EBV and was the only patient with adenovirus detected) – had **markedly higher** IFN-I autoantibody levels than all other patients ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=HAdV%20was%20detected%20in%20a,the%20time%20of%20sputum%20collection)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=present%20study%2C%20that%20the%20majority,severe%20and%2For%20very%20severe%20symptoms)). Similarly, among the control groups, the only person with elevated anti-IFN autoantibodies was an immunosuppressed 77-year-old (the “positive” control who had multiple chronic viruses active) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=level%2Fmore%20frequent%20release%20of%20the,up)). In other words, *in rare cases of extreme immune dysfunction*, anti-interferon antibodies were present in ME/CFS, but the majority of mild-to-moderate patients did not have them ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=present%20study%2C%20that%20the%20majority,severe%20and%2For%20very%20severe%20symptoms)).

These findings imply that IFN-I autoantibodies are **not common** in the general ME/CFS population, but they *might* emerge in a subset of very severe patients who experience uncontrolled viral replication. One interpretation is that chronic stimulation by reactivated viruses (EBV, adenovirus, etc.) in those patients could drive the production of anti-cytokine antibodies, further blunting their antiviral immunity ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=level%2Fmore%20frequent%20release%20of%20the,up)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=patient%20expressing%20HAdV%20and%20EBV%2C,15)). The observation that the sickest patient (wheelchair-bound, harboring EBV+HAdV) had anti-IFN-I Abs suggests a possible “failure point” where the immune system goes from exhausted to actively self-sabotaging. It also mirrors the risk factors seen in COVID (elderly, male, or immunocompromised patients were more likely to have these auto-Abs ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=AutoAbs%20to%20IFN,disseminated%20viral%20infections%20caused%20by))). At present, the **significance** of IFN-I autoantibodies in ME/CFS remains unclear due to the low incidence. Their presence in an isolated severe case means they could contribute to especially poor viral control in that individual, but population-wide they do not explain the immune dysfunction of ME/CFS. Researchers have concluded that impaired interferon signaling in ME/CFS is more likely due to cell-intrinsic exhaustion or other regulatory factors than due to IFN autoantibodies in most patients ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=level%2Fmore%20frequent%20release%20of%20the,up)). Still, this finding raises a practical point: *testing* for anti-IFN-I antibodies in patients with severe or very atypical ME/CFS could be worthwhile, as a positive result might point to targeted treatments (for example, plasmapheresis or IFN therapy). In summary, **auto-IFN-I antibodies are not a hallmark of ME/CFS** generally, but they may identify a rare subset of patients with an extreme antiviral immune deficit. This underscores the heterogeneity of ME/CFS immune profiles and the importance of individualized assessment.

## Interplay of Viral Reactivation, Immune Collapse, and Autonomic Dysregulation  
 ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/)) *Figure 1: Schematic of proposed ME/CFS pathophysiology involving viral reactivation and multi-system dysregulation. Latent viruses (e.g., EBV, HHV-6) can be reactivated by new infections or stressors, leading to viral products (such as EBV dUTPase or endogenous retrovirus activation) that stimulate chronic immune responses. This persistent immune activation (center) can trigger neuroinflammation in the central nervous system (altered microglia/astrocyte activity) and disrupt the autonomic nervous system, as well as cause systemic inflammation and metabolic dysfunction. Key findings include release of viral proteins like dUTPases that induce cytokines (IL-6, IL-1β, TNF-α) from microglia/astrocytes and alter T-cell responses (e.g., IL-21 from CD4 T-cells) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=diminished%20ability%20to%20regulate%20the,inflammatory%20cytokines%20%5B18%5D%2C%20and)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Similarly%2C%20HHV,6%2C%20in%20the)). These, in turn, can lead to symptoms across multiple systems (brain, gut, immune, metabolic). [Adapted from Broderick *et al.*, 2024 ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Viewed%20together%2C%20patients%E2%80%99%20reports%20of,6A%20dUTPase%20antibodies%20%5B%2036)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=making%20them%20susceptible%20to%20health,inflammatory%20cytokines%20%5B%2036%5D%2C%20and))]*

A central question is *how* viral reactivations and immune dysfunction tie together to produce the chronic illness of ME/CFS. Under normal conditions, the immune system maintains a **balance** with latent viruses – a kind of truce where viruses stay quiet and the host keeps them in check (often at mucosal surfaces) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=,Immune%20Balance)). ME/CFS appears to represent a breakdown of this homeostasis, wherein an initial stressor (often an infection) tips the system into a chronic inflammatory state that it cannot exit ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=not%20subside%20rapidly%20to%20a,mean%20they%20continue%20to%20be)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Autoimmunity%20and%20chronic%20viral%20infections,53)). Recent theories emphasize a **“mucosal immune buffering” collapse**: the idea that the first line of defense (e.g., in the oral/nasal mucosa) fails to contain latent viruses, leading to abnormal viral replication and an overactive immune response that spills systemically. For instance, patients have significantly elevated EBV-specific antibodies in saliva/mucus (mucosal IgA) compared to controls ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=autoAbs%20to%20IFN,one%20control%20participant%2C%20treated%20with)), indicating frequent viral activity at mucosal surfaces and constant immune stimulation. If this antiviral response “never switches off,” it could drive a persistent inflammatory signaling.

**Immune Exhaustion and Chronic Inflammation:** Tate *et al.* (2023) describes a scenario wherein a normal acute immune response to infection does not properly resolve in ME/CFS patients ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=not%20subside%20rapidly%20to%20a,mean%20they%20continue%20to%20be)). The transient inflammation fails to subside, and instead a *chronic* immune activation ensues with the body perceiving a continued threat even after the original pathogen is gone ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=not%20subside%20rapidly%20to%20a,mean%20they%20continue%20to%20be)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=response%20becomes%20chronic%20and%20dysregulated,longer%20being%20any%20outside%20danger)). This is supported by gene expression and proteomic studies showing ongoing low-grade inflammation in ME/CFS even years into the illness ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Trained%20immunity%20has%20recently%20emerged,prolonging%20a%20chronic%20inflammatory%20state)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Trained%20immunity%2C%20coupled%20with%20hyperactivation,of%20the%20immune%20%2Finflammatory%20system)). What might cause the immune system to get “stuck” in high gear? One proposed factor is a failure in regulatory T cells (Tregs). Simulations of Treg dynamics suggest that if a person has a certain predisposition (for example, a high “autoimmune potential” in their T-cell clones), even a *mild* infection could tip them into a state of unchecked immune activation ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Autoimmunity%20and%20chronic%20viral%20infections,53)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=candidates%20to%20be%20involved%20with,53)). Essentially, the normal feedback loops that terminate an immune response may be impaired, perhaps by genetic factors or by the virus itself. EBV is a prime suspect because it infects B cells and can skew immune regulation; indeed, some ME/CFS patients show *deficient EBV-specific T-cell memory*, meaning they respond poorly to latent EBV and fail to control its reactivation ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=coupling%20EBV%20reactivation%2C%20ME%2FCFS%20onset%2C,EBV%20dUTPase%20has%20also%20been)). Such patients could experience frequent viral antigen exposure that drives chronic cytokine production and “immune exhaustion” profiles (low NK cell function, altered T cell metabolism, etc., as documented in ME/CFS cohorts ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Viewed%20together%2C%20patients%E2%80%99%20reports%20of,6A%20dUTPase%20antibodies%20%5B%2036)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=ME%2FCFS%20is%20typically%20characterized%20by,6A%20dUTPase%20antibodies%20%5B18))).

**Autonomic Nervous System (ANS) Involvement:** Chronic immune activation does not only produce flu-like symptoms; it can also disrupt the autonomic nervous system. The ANS (which controls heart rate, blood pressure, digestion, etc.) is highly sensitive to inflammatory cytokines and stress signals. In ME/CFS, immune dysregulation and autonomic dysregulation often go hand-in-hand ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=proposes%20that%20viruses%20trigger%20the,role%20in%20several%20autoimmune%20diseases)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=proposes%20that%20viruses%20trigger%20the,play%20a%20pathogenic%20role%20in)). For example, high levels of inflammatory cytokines (like IL-6 or TNF) can trigger sympathetic nervous system surges or vagus nerve signaling that contribute to symptoms like orthostatic intolerance, tachycardia, and gastrointestinal disturbances. Conversely, autonomic dysfunction (say, reduced blood flow or high cortisol from stress) can impair immune cell trafficking and function ([
            Converging Evidence of Similar Symptomatology of ME/CFS and PASC Indicating Multisystemic Dyshomeostasis - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9855891/#:~:text=)) ([
            Converging Evidence of Similar Symptomatology of ME/CFS and PASC Indicating Multisystemic Dyshomeostasis - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9855891/#:~:text=Stress%20is%20known%20to%20suppress,hypothesized%20aberrant%20homeostasis%20can%20be)), creating a vicious cycle. A telling clue is the presence of **autoantibodies against autonomic receptors** in many ME/CFS patients: researchers have found elevated IgG against β_2_-adrenergic receptors and M3/M4 muscarinic acetylcholine receptors in a substantial subset of patients ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=A%20study%20published%20in%202020,10)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=A%20study%20published%20in%202020,10)). These are receptors that regulate vasodilation, heart rate, and neurotransmission. If antibodies blunt their function, one would expect blood vessel constriction, reduced cerebral blood flow, orthostatic intolerance and other dysautonomic features – all of which are seen in ME/CFS ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=A%20study%20published%20in%202020,10)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=AChR%20and%20M4%20AChR,10)). In fact, the presence of these antibodies and the observed autonomic symptoms led some authors to propose ME/CFS as an autoimmune *neurological* disease of the neurovascular system ([Wirth-Scheibenbogen hypothesis - MEpedia](https://me-pedia.org/wiki/Wirth-Scheibenbogen_hypothesis#:~:text=Hypothesis%5Bedit%20%20)).

How might viral reactivation tie into autonomic autoimmunity? One mechanism is **molecular mimicry**: viruses like EBV can trigger antibodies that cross-react with host proteins. EBV, HHV-6, and others infect immune cells and can create a context for loss of tolerance. The chronic B-cell activation in ME/CFS (e.g., elevated B-cell activating factor and autoantibodies reported ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Viewed%20together%2C%20patients%E2%80%99%20reports%20of,6A%20dUTPase%20antibodies%20%5B%2036)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=ME%2FCFS%20is%20typically%20characterized%20by,6A%20dUTPase%20antibodies%20%5B18))) suggests the immune system may start targeting neurotransmitter receptors after being overstimulated by persistent viral antigens. Researchers Gravelsina *et al.* note that “infection-triggered disease onset, chronic immune activation, and autonomic dysregulation in ME/CFS point to an autoimmune disease involving neurotransmitter receptors” ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=proposes%20that%20viruses%20trigger%20the,role%20in%20several%20autoimmune%20diseases)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=onset%2C%20chronic%20immune%20activation%2C%20and,role%20in%20several%20autoimmune%20diseases)). In their view, a viral trigger could initiate an autoimmune loop: the virus causes initial inflammation, which leads to autoantibody production against autonomic receptors, which then causes symptoms (and potentially further immune dysregulation). Supporting this, they cite that many patients show both **markers of viral reactivation and autoimmunity simultaneously** ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)). For instance, a patient with high HHV-6 load tended to also have higher anti-M4 acetylcholine receptor antibody levels ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)). This entwining of infectious and autoimmune processes can create a self-perpetuating cycle.

**“Vicious Circles” and Multi-System Effects:** Several integrative models have been proposed to explain how these processes feed back on each other and why the illness becomes chronic. One hypothesis by Wirth and Scheibenbogen (2020–2021) posits that an infection triggers autoantibodies to β_2_-adrenergic receptors, which causes **ANS dysfunction and microcirculatory deficits** ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=Chronic%20Fatigue%20Syndrome%20or%20Myalgic,An%20enigmatic%20bioenergetic%20disturbance)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=against%20%C3%9F2,Excessive%20generation%20of)). Specifically, they argue that *β_2_-adrenergic receptor dysfunction* leads to excessive sympathetic activity and blood vessel dysregulation – effectively, blood vessels don’t dilate properly in response to demand. In the brain and muscles, this means reduced blood flow and oxygen delivery (brain fog, fatigue), which in turn forces muscles to compensate by releasing local vasodilators (like lactate, adenosine, etc.) to get blood. Wirth et al. describe how an “enigmatic bioenergetic disturbance” in ME/CFS muscles causes an over-release of these vasodilating substances (some of which also cause pain) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=the%20presence%20of%20vascular%20dysregulation,and%20merged%20with%20the%20first)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=in%20skeletal%20muscle%20strongly%20contributes,presume%20that%20dysfunction%20of%20the)). These substances spill into circulation, lowering blood volume (causing *hypovolemia*) and paradoxically suppressing renin/aldosterone (an observed “paradox” in ME/CFS) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=the%20presence%20of%20vascular%20dysregulation,and%20merged%20with%20the%20first)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=in%20skeletal%20muscle%20strongly%20contributes,ATPase%20causing)). The net effect is to worsen orthostatic intolerance and perpetuate poor perfusion. Meanwhile, the lack of proper β_2_ signaling in muscle also means ion pumps (like the Na^+/K^+ ATPase) are not stimulated, leading to ionic imbalances in muscle cells (sodium and calcium overload) that impair mitochondrial function ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=hypothesis,to%20explain%20postexertional%20malaise)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=in%20skeletal%20muscles,ATPase%20activity%20is%20not)). This cellular metabolic crash then further reduces energy output, contributing to *post-exertional malaise* and prolonging recovery ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=%C3%9F2AdR%20also%20leads%20to%20an,ATPase%20activity%20is%20not)). Wirth and Scheibenbogen call this a **“vicious circle”**: diminished receptor signaling → poor circulation → metabolic waste buildup → pain and autonomic feedback → further metabolic impairment ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=hypothesis,to%20explain%20postexertional%20malaise)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=exchanger%20,ATPase%20activity%20is%20not)). It’s essentially a self-reinforcing loop linking the immune (autoantibodies), cardiovascular (vessel tone), and metabolic systems, explaining how a one-time hit (infection) could lead to a chronic state. This model aligns with clinical observations that when patients push beyond their limits, they enter a crash state that is disproportionate and self-sustaining.

Another example of an interactive model involves EBV: EBV reactivation produces a protein (EBV dUTPase) that has *potent immunomodulatory effects*. It can stimulate Toll-like receptors and cause microglia and astrocytes to secrete IL-1β, IL-6, TNF-α ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=diminished%20ability%20to%20regulate%20the,inflammatory%20cytokines%20%5B18%5D%2C%20and)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=possesses%20immunomodulatory%20properties%20,inflammatory%20cytokines%20%5B%2036%5D%2C%20and)), leading to **neuroinflammation**. Chronic neuroinflammation has indeed been detected in ME/CFS brains via PET scans (activated glial cells in cingulate cortex, hippocampus, etc.) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=become%20the%20dominant%20features%20and,PET)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=the%20specific%20components%20of%20the,patients%20with%20varying%20severity%20of)). EBV dUTPase can also skew T-cell responses (increasing T_fh helper cells and IL-21) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=possesses%20immunomodulatory%20properties%20,%CE%B1%20in)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=shown%20to%20induce%20the%20expression,infection%20to%20ME%2FCFS%20onset%20hinder)), which could exacerbate B-cell activation and autoimmunity. Thus EBV could serve as a molecular *trigger* that continuously presses the immune system’s “on button” and perturbs neural circuits. Some authors have gone so far as to suggest EBV causes an acquired immunodeficiency syndrome in ME/CFS by forming ectopic lymphoid aggregates in tissues that sustain inflammation ([Review - Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID?, 2023, Ruiz-Pablos et al | Science for ME](https://www.s4me.info/threads/epstein-barr-virus-acquired-immunodeficiency-in-myalgic-encephalomyelitis-is-it-present-in-long-covid-2023-ruiz-pablos-et-al.35322/#:~:text=,immunodeficiency%2C%20further%20weakening%20the%20body%27s)), although this hypothesis is still speculative. What is clear is that **chronic infection and inflammation beget one another**: persistent viral antigens drive ongoing immune activation, and an impaired immune system in turn fails to eliminate the virus – a classic positive feedback loop.

## Nonlinear Dynamics and “Attractor-Like” Disease States in ME/CFS  
One striking aspect of ME/CFS is how stable and self-sustaining the illness can become in many patients. People often report a “before and after” threshold – once they developed ME/CFS, their body shifted into a new, persistent state of dysfunction that waxes and wanes but doesn’t simply revert to normal. This has led scientists to describe ME/CFS as a potential **nonlinear dynamic** problem, where the body’s regulatory networks settle into an alternative equilibrium (a disease *attractor state*). In other words, the interaction loops described above may lock the system into a chronic pathology that is hard to escape. Mathematical modelers have started to approach ME/CFS in this framework. For example, a 2019 computational model by Marshall-Gradisnik’s group (Broderick *et al.*) proposed that ME/CFS involves a **“new pathogenic equilibrium”** across the endocrine-immune network ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=The%20complex%20and%20varied%20presentation,target%20therapies)). Their model of 28 interconnected hormonal and immune markers suggested that changes in regulatory feedback (e.g., between the HPA axis and cytokine signaling) could explain the *persistence* of ME/CFS, and that the *robustness* of this new equilibrium might underlie why single-target treatments often fail ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=The%20complex%20and%20varied%20presentation,target%20therapies)). Essentially, once the system has transitioned to this chronic state, simply blocking one cytokine or one receptor is not enough to reset the network – multiple feedback loops maintain the ill state ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=The%20complex%20and%20varied%20presentation,target%20therapies)).

Clinical observations support the idea of nonlinear dynamics. Patients often experience **non-linear responses to exertion or stress** – a small additional stress can trigger a massive crash (disproportionate output to input). This is reminiscent of a system operating near a critical threshold. Wirth and Scheibenbogen, in their muscle hypothesis, noted that *once a severe episode has occurred*, the “threshold for re-induction” of the dysfunction is strongly lowered ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=increased%20proton%20production%20raises%20intracellular,dysfunction%20to%20perpetuate%20the%20disease)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=occurred%20in%20a%20severe%20manner,dysfunction%20to%20perpetuate%20the%20disease)). After a major crash, even minor activities can re-trigger the whole cascade of mitochondrial and vascular dysfunction, “perpetuating the disease” ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=increased%20proton%20production%20raises%20intracellular,dysfunction%20to%20perpetuate%20the%20disease)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=occurred%20in%20a%20severe%20manner,dysfunction%20to%20perpetuate%20the%20disease)). This suggests hysteresis – the system remembers the crash and remains sensitized, which is a hallmark of nonlinear systems with multiple stable states. Another example is the phenomenon of **“push-crash” cycles** (post-exertional malaise): patients might manage okay below a certain activity limit, but crossing that limit produces a crash that can last days or weeks. Over time, many patients learn they must stay within a narrow envelope of activity to avoid catastrophic relapse. This behavior is consistent with the body oscillating around a precarious setpoint, where small perturbations can lead to outsized, prolonged deviations (and recovery is slow and non-linear).

From a theoretical perspective, ME/CFS may involve *positive feedback loops* that create a self-sustaining circuit. For instance: latent virus → immune activation → autonomic stress → poor perfusion/metabolism → incomplete virus clearance → more viral reactivation → further immune activation. If each step reinforces the next, the system can become autocatalytic. Researchers have drawn parallels to conditions like sepsis or cytokine storms, except in ME/CFS the feedback is at a lower amplitude but chronic. One newly introduced concept is **trained immunity**: after an infection, the innate immune system can remain in a primed state (with epigenetic changes) that leads to hyper-reactive inflammatory responses later ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Trained%20immunity%20has%20recently%20emerged,prolonging%20a%20chronic%20inflammatory%20state)) ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=Trained%20immunity%2C%20coupled%20with%20hyperactivation,of%20the%20immune%20%2Finflammatory%20system)). In ME/CFS, trained innate immunity might contribute to a chronic pro-inflammatory bias – essentially a “hardwired” attractor in the immune network. Coupled with an attenuated counter-regulation (e.g., dysfunctional Tregs or autonomic imbalances), this could stabilize the system in an ill state.

Another lens is metabolic trapping. Although primarily a metabolic hypothesis, Robert Phair’s 2019 idea of a “metabolic trap” (where a vital enzyme like IDO2 gets stuck in one configuration, causing tryptophan pathway blockage) is an example of an alternative stable state at the cellular level. If such a trap exists, the challenge is how to perturb the system out of it. Rintatolimod (Ampligen) and other immunomodulators have been tried, and interestingly the modeling by Broderick *et al.* predicted that **different initial cytokine/hormone states** might determine whether a treatment like rintatolimod can push a patient’s system back toward health ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=Mechanistically%20informed%20predictions%20of%20endocrine,predicted%20to%20support%20partial%20remission)) ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=in%20a%20smaller%20subset%20of,12%2C%20and%20B%20cell%20activation)). This again underscores that there may not be a single universal switch to flip; the path out of the “attractor” could vary by individual depending on which feedback loops are dominant in their case.

In summary, an emerging view is that ME/CFS is maintained by **nonlinear feedback loops** between the immune system, the nervous system, and metabolism. The disease behaves more like a network that has entered a maladaptive steady-state than a one-time injury that heals. This perspective encourages combination therapies or phased interventions to nudge the system gradually back to normal. It also implies that early intervention (before the network fully entrains into the sick state) might prevent chronic ME/CFS – an insight especially relevant in the context of long COVID cases. Ongoing research into dynamical biomarkers (like heart rate variability, cytokine network connectivity, etc.) aims to further elucidate these complex feedback relationships.

## Emerging Biomarkers and Subgroup Stratification  
Given the heterogeneity of ME/CFS, there is a pressing need for biomarkers that can **stratify patients into subtypes** and guide targeted treatments. Recent studies suggest that combining viral and immunological markers could delineate meaningful subgroups. One intuitive framework is to distinguish an “infectious subtype” and an “autoimmune subtype,” while recognizing they can overlap ([BHC Collaborates on NIH Funded Study to Identify ME/CFS Antibody Biomarkers - Bateman Horne Center](https://batemanhornecenter.org/identifyantibodybiomarkers/#:~:text=response%20called%20autoimmunity,subtype%20from%20gastrointestinal%20ME%2FCFS%20subtype)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)). In fact, evidence indicates many ME/CFS patients show *both* persistent viral factors and autoimmune features – so the more practical approach may be to measure several biomarkers and identify each patient’s unique profile. Here we highlight some candidate markers and stratification schemes: 

- **Viral Load and Serological Markers:** As reviewed, a subset of patients have demonstrable viral reactivations (e.g., high EBV DNA in sputum or HHV-6 DNA in blood). These patients might be identified by positive PCR or elevated viral capsid antigen/early antigen titers. For example, someone who consistently sheds EBV or has rising HHV-6 IgM could be classified as “virus-high.” This could inform treatment, as such a patient might benefit from antivirals or immunoglobulin therapy aimed at controlling herpesviruses. In the past, small trials of antivirals (valganciclovir, e.g., by Montoya et al.) showed improvements in the subset of ME/CFS patients with elevated antibody titers to EBV/HHV-6, supporting the idea of a viral-load-defined subgroup. More recently, **HHV-6 load** in blood was found to correlate with disease severity ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)), and **EBV early antigen antibodies** have been tied to symptom severity in some cohorts ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=making%20them%20susceptible%20to%20health,inflammatory%20cytokines%20%5B%2036%5D%2C%20and)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=astrocytes%20,infection%20to%20ME%2FCFS%20onset%20hinder)). These could serve as inclusion criteria for antivirals in clinical trials. Additionally, serology for past acute infections (such as Coxsackie/enteroviruses, parvovirus, etc.) might identify a post-viral onset subgroup.

- **Autoantibodies (Immune and Autonomic):** Immunological assays have revealed several autoantibodies enriched in ME/CFS. Notably, antibodies against **β_2-adrenergic receptors** and **M3/M4 muscarinic acetylcholine receptors** are elevated in patients vs. controls (median levels ~1.4 ng/mL vs 0.8 for anti-β_2_ ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=more%20than%201%2C000%20copies%2F10,did%20not%20show%20any%20difference)), and 8.15 vs 6.45 ng/mL for anti-M4 ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=with%20severe%20ME%2FCFS%2C%20in%2018%2F73,The)), both significant). These autoantibodies did not differ by disease severity – even mild patients had them above healthy levels ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=more%20than%201%2C000%20copies%2F10,M4%20level)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=anti,their%20usage%20as%20clinical%20biomarkers)) – suggesting they could serve as **general biomarkers** for ME/CFS. Gravelsina *et al.* argue that measuring these receptor autoantibodies could be useful in the “diagnostic algorithm” for ME/CFS ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=severity,their%20usage%20as%20clinical%20biomarkers)). Beyond diagnosis, they might stratify an “autoimmune neuro receptor” subtype. Patients with very high levels might benefit from therapies like IVIG, plasmapheresis, or B-cell depletion. Indeed, a subset of ME/CFS patients with these autoantibodies showed clinical improvement in a pilot **immunoadsorption (IgG depletion) trial**, hinting that we can target this autoimmune component. Other autoantibodies proposed in ME/CFS include those against nuclear envelope laminin, adrenergic α_1_ receptors, and cytokines (IFN-I as discussed, though rare). Each could define a small subgroup. For instance, if a patient tests positive for anti-IFN-I or anti-IL-2 autoantibodies, they might represent an “immune-suppressed” end of the spectrum and could be treated accordingly (perhaps with interferon therapy or protective isolation during infections).

- **Cytokine and Inflammation Profiles:** Numerous studies have tried to find a cytokine signature for ME/CFS, with varying results. One consistent finding is a **shift in cytokines with disease duration** – early in illness more pro-inflammatory and antiviral cytokines are elevated, whereas long-term patients sometimes show a subdued or compensatory anti-inflammatory profile (e.g. elevated TGF-β) ([Cytokine signature associated with disease severity in chronic ...](https://www.pnas.org/doi/10.1073/pnas.1710519114#:~:text=Cytokine%20signature%20associated%20with%20disease,systems%20against%20unremitting%20inflammation)). A landmark 2015 study by Hornig et al. found that patients ill <3 years had a distinctly different immune profile than those ill >3 years. Such temporal patterns suggest stratifying by illness stage. Another approach is severity: a 2017 study in *PNAS* found a cytokine pattern (including IL-1α, IL-4, IL-6, IL-12, IFN-γ differences) that correlated with symptom severity in ME/CFS ([Cytokine signature associated with disease severity in chronic ...](https://www.pnas.org/doi/10.1073/pnas.1710519114#:~:text=Cytokine%20signature%20associated%20with%20disease,systems%20against%20unremitting%20inflammation)). So, measuring a panel of cytokines might distinguish a highly inflammatory subset from a more immune-exhausted subset. Those with ongoing high inflammation might benefit from anti-inflammatories or cytokine blockers, whereas those with immune exhaustion might need immune stimulants or modulators. Additionally, markers like **activin A** (a cytokine in TGF-β family) and **IL-21** have been proposed as biomarkers – one study found these were elevated specifically in patients who had antibodies to EBV and HHV-6 dUTPase (indicating past reactivation of those viruses) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Viewed%20together%2C%20patients%E2%80%99%20reports%20of,6A%20dUTPase%20antibodies%20%5B%2036)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=ME%2FCFS%20is%20typically%20characterized%20by,6A%20dUTPase%20antibodies%20%5B18)). This suggests a combined viral-immune biomarker signature: if someone has antibodies to viral proteins (dUTPase) *and* high activin A, they might be in a subgroup driven by smoldering virus-induced inflammation.

- **Gene Expression and Metabolomics:** Though beyond the scope of this viral/immunologic focus, it’s worth noting that unsupervised analyses (clustering) of gene expression and metabolite data have consistently identified **multiple subgroups** of ME/CFS. For example, a 2008 gene expression study found seven distinct subtypes with differences in clinical presentation ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=One%20of%20the%20earliest%20descriptions,from%20patients%20revealed%20seven%20distinct)). More recently, a Spanish study (2021) using machine learning on symptom and lab data described five subtypes ([Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID](https://www.mdpi.com/1422-0067/24/6/5124#:~:text=with%20time%20lending%20weight%20toward,clinical%20phenotypes%20coupled%20with%20multiple)). These often don’t have clear-cut biological labels, but they reinforce the need for stratification. Some patients predominantly have **pain and neuroinflammatory features**, others have **orthostatic intolerance and blood volume issues**, others have **energy metabolism abnormalities**. In practice, a clinician might use a combination of **biomarkers** to assign a patient to a subtype (for example: high EBV load + low NK cell function + high IL-2 suggests an “infection-induced immunodeficiency” subtype, whereas high ANA titer + β_2AR autoantibodies suggests an “autoimmune” subtype). The Bateman Horne Center and others have advocated for precisely this: using antibody panels to differentiate a “viral subtype” from an “autoimmune subtype” from a “gut dysbiosis subtype,” etc. ([BHC Collaborates on NIH Funded Study to Identify ME/CFS Antibody Biomarkers - Bateman Horne Center](https://batemanhornecenter.org/identifyantibodybiomarkers/#:~:text=response%20called%20autoimmunity,subtype%20from%20gastrointestinal%20ME%2FCFS%20subtype)). Such subgrouping could allow more tailored therapies – antivirals, immunotherapies, microbiome interventions – rather than a one-size-fits-all approach.

Importantly, these categories are not mutually exclusive. As one paper eloquently stated, *“the group triggered by viral infection could also have markers of autoimmunity”* ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=groups%2Fsubsets%2C%20one%20of%20which%20is,course%20severity%2C%20the%20presence%20of)). Many patients likely cycle through mechanisms – an initial viral hit leads to autoimmunity, which then causes autonomic dysfunction that further impairs immune surveillance, allowing other latent viruses to reactivate, and so on. Therefore, a **combinatorial biomarker profile** may be most informative. For instance, measuring both viral DNA load and autoantibodies in the same patient could identify a high-risk subset: a recent suggestion is that patients who have **high viral loads + anti-IFN-I autoantibodies** (if any are found) would represent a severe immunocompromised subgroup who might need aggressive antiviral and immunotherapy ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=present%20study%2C%20that%20the%20majority,severe%20and%2For%20very%20severe%20symptoms)). Likewise, patients with **elevated HHV-6 load + high β_2/M4 autoantibodies** might benefit from a combination of antiviral (to reduce viral stimulus) and immunomodulatory treatment (to address autoimmunity) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=however%2C%20increased%20viral%20load%20correlates,levels%20of%20antibodies%20against%20%CE%B22AdR)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=severity,their%20usage%20as%20clinical%20biomarkers)). On the other hand, patients with no viral markers but clear autoimmune/inflammatory markers might be candidates for immunosuppressants or apheresis, whereas those with no obvious immune or viral markers (if any exist) might be treated by symptomatic and supportive strategies (e.g., energy metabolism enhancers).

In summary, researchers are converging on the idea that ME/CFS is **not a single entity** but a spectrum of overlapping subgroups. Viral reactivation markers (EBV, HHV-6, etc.) and immune markers (autoantibodies to IFN or receptors, cytokine levels) are among the most promising for defining these subtypes ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=etiology%2C%20and%20another%20one%20is,course%20severity%2C%20the%20presence%20of)). A 2022 review explicitly hypothesized a division between a primarily autoimmune subset and a primarily virus-triggered subset, with the caveat that these intersect and evolve over time ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)). The ultimate goal is to use such biomarkers to tailor treatments – for example, directing antivirals to those who will actually benefit, and not to those who won’t. As large datasets from long COVID and ME/CFS research accumulate, machine learning may further refine stratification, perhaps identifying composite biomarker signatures that predict treatment response. This personalized approach offers hope to break the “one size fits all” stalemate in ME/CFS therapeutics.

## Conclusion  
The period 2020–2025 has seen significant advances in our understanding of ME/CFS as a condition involving chronic viral immune interactions and system-wide dysregulation. Key findings include evidence that herpesviruses like EBV (and to a lesser extent HHV-6/7) are frequently reactivated or present at higher loads in ME/CFS patients compared to healthy people ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=assessing%20the%20active%20,symptom%20severity%20are%20not%20fully)), especially in tissues and mucosal compartments that standard blood tests can miss ([
            Tissue specific signature of HHV-6 infection in ME/CFS - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9795011/#:~:text=specific%20localization%20of%20active%20HHV,between%20herpesvirus%20infection%20and%20ME%2FCFS)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=We%20found%20that%20ME%2FCFS%20patients,cell)). This chronic viral antigen exposure may contribute to the well-documented immune dysfunction in ME/CFS – characterized by an “exhausted” antiviral profile, low NK cell activity, and a mix of inflammatory and regulatory cytokine imbalances ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=Viewed%20together%2C%20patients%E2%80%99%20reports%20of,6A%20dUTPase%20antibodies%20%5B%2036)) ([
            Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): challenges and opportunities - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795702/#:~:text=ME%2FCFS%20is%20typically%20characterized%20by,6A%20dUTPase%20antibodies%20%5B18)). While the feared *type I interferon autoantibodies* that cause severe COVID-19 generally do not appear in ME/CFS (apart from rare severe cases) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=level%2Fmore%20frequent%20release%20of%20the,up)) ([Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients](https://www.mdpi.com/1999-4915/17/3/422#:~:text=present%20study%2C%20that%20the%20majority,severe%20and%2For%20very%20severe%20symptoms)), the immune system in ME/CFS shows other signs of autoimmunity, such as autoantibodies against autonomic receptors, which bridge the gap between immune and nervous system dysfunction ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=proposes%20that%20viruses%20trigger%20the,role%20in%20several%20autoimmune%20diseases)) ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=A%20study%20published%20in%202020,10)). Multiple models now depict ME/CFS as a self-sustaining network of positive feedback loops: latent viruses and possibly gut or environmental triggers keep the immune system in a chronic inflammatory state, which in turn alters autonomic regulation and cellular metabolism, locking the body into a low-energy, high-inflammation mode ([
            Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC6478538/#:~:text=The%20complex%20and%20varied%20presentation,target%20therapies)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=hypothesis,to%20explain%20postexertional%20malaise)). These feedback loops create a nonlinear disease course, explaining hallmark features like post-exertional “crashes” and the difficulty of reversing the illness once established ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=increased%20proton%20production%20raises%20intracellular,dysfunction%20to%20perpetuate%20the%20disease)) ([Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - PubMed](https://pubmed.ncbi.nlm.nih.gov/33882940/#:~:text=occurred%20in%20a%20severe%20manner,dysfunction%20to%20perpetuate%20the%20disease)).

On a hopeful note, recognizing these loops also suggests points of intervention. For instance, breaking the cycle at multiple points – *combining* an antiviral (to reduce antigen load) with an immunotherapy (to reset immune responses) and autonomic support (e.g., volume expansion, β-blockers or midodrine for POTS) – might be necessary to shift a patient’s system back toward health. Stratifying patients by biomarkers will be crucial for such targeted approaches. Recent work supports using a **panel of biomarkers** – viral DNA or protein tests, antibody profiles, cytokines – to subgroup patients ([
            Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome - PMC
        ](https://pmc.ncbi.nlm.nih.gov/articles/PMC9589447/#:~:text=We%20hypothesize%20that%20the%20cohort,course%20severity%2C%20the%20presence%20of)). This could finally allow clinical trials to enroll more homogeneous groups, increasing the chance of detecting treatment efficacy within a subset. For example, an anti-EBV drug or a therapeutic vaccine might be trialed in the subgroup with active EBV markers, whereas immunoadsorption or B-cell therapy might be trialed in the subgroup with high receptor autoantibodies. Early results (though preliminary) like the improvement of some patients after IgG autoantibody removal, or the historical success of antivirals in high-viral-load patients, validate this strategy.

In conclusion, the interplay of viral reactivation and immune dysfunction in ME/CFS is increasingly well-documented. ME/CFS can no longer be considered a “mystery illness”; instead, it is coming into view as a complex syndrome of **immune dysregulation with identifiable biological signals**. EBV and HHV-6 reactivations are one such signal, type I IFN activity (or lack thereof) is another, and autonomic autoimmune markers yet another. These insights are driving a paradigm shift toward mechanism-based classification of ME/CFS. With continued research – including longitudinal studies following infection cohorts (like COVID-19 survivors) – we are likely to further unravel the nonlinear dynamics of ME/CFS. This will pave the way for rational therapies aimed at unlocking the immune-autonomic metabolic “gridlock” that traps patients, ultimately restoring normal homeostasis. The hope is that in the coming years, clinicians will be able to run a panel of tests and say, for example: *“You have ME/CFS of the viral-reactivation dominant subtype with some autoimmunity – we will treat the virus and calm the immune system”*, thereby personalizing treatment. Such an approach, grounded in the latest literature, offers a roadmap to improve outcomes in this challenging and often devastating illness.

**Sources:** Recent peer-reviewed studies and reviews (2020–2025) have been cited throughout this report, indicated by bracketed references. Each reference corresponds to the source listed, for example, as 【6】 Nilsson *et al.*, 2025, **Viruses** journal, lines 688–696, or 【64】 Gravelsina *et al.*, 2022, **Front. Immunol.**, lines 277–285, etc. These provide the evidentiary basis for the statements made. The reader is encouraged to consult these sources for further details on methodology and context.
